CA2320104A1 - Procede de prevention et de traitement d'un trouble d'hypersensibilite de type i - Google Patents

Procede de prevention et de traitement d'un trouble d'hypersensibilite de type i Download PDF

Info

Publication number
CA2320104A1
CA2320104A1 CA002320104A CA2320104A CA2320104A1 CA 2320104 A1 CA2320104 A1 CA 2320104A1 CA 002320104 A CA002320104 A CA 002320104A CA 2320104 A CA2320104 A CA 2320104A CA 2320104 A1 CA2320104 A1 CA 2320104A1
Authority
CA
Canada
Prior art keywords
antibodies
animal
asthmatic
asthma
exacerbations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002320104A
Other languages
English (en)
Inventor
Barry Michael Ronald Woloski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Cangene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cangene Corp filed Critical Cangene Corp
Publication of CA2320104A1 publication Critical patent/CA2320104A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'administration d'anticorps Rh à un animal, est efficace pour la réduction de l'intensité, la durée ou la fréquence d'exacerbations asthmatiques et d'autres troubles d'hypersensibilité de type I. L'invention porte sur les compositions desdits anticorps et leurs utilisation pour prévenir ces troubles. Le traitement aux anticorps Rh desdits mammifères, peut également permettre de réduire le dosage de médicaments concomitants ou autres, nécessaires à l'animal pour la lutte contre cette maladie.
CA002320104A 1998-02-10 1999-02-09 Procede de prevention et de traitement d'un trouble d'hypersensibilite de type i Abandoned CA2320104A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7426998P 1998-02-10 1998-02-10
US60/074,269 1998-02-10
US9252898P 1998-07-13 1998-07-13
US60/092,528 1998-07-13
PCT/CA1999/000109 WO1999040939A1 (fr) 1998-02-10 1999-02-09 Procede de prevention et de traitement d'un trouble d'hypersensibilite de type 1

Publications (1)

Publication Number Publication Date
CA2320104A1 true CA2320104A1 (fr) 1999-08-19

Family

ID=26755448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002320104A Abandoned CA2320104A1 (fr) 1998-02-10 1999-02-09 Procede de prevention et de traitement d'un trouble d'hypersensibilite de type i

Country Status (3)

Country Link
AU (1) AU2505599A (fr)
CA (1) CA2320104A1 (fr)
WO (1) WO1999040939A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724182B1 (fr) * 1994-09-02 1996-12-13 Pasteur Institut Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations

Also Published As

Publication number Publication date
WO1999040939A1 (fr) 1999-08-19
AU2505599A (en) 1999-08-30

Similar Documents

Publication Publication Date Title
US8178098B2 (en) Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20210130451A1 (en) Treatment for rheumatoid arthritis
Engelhard et al. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia
EP1596880B1 (fr) Methodes et compositions pour supprimer la differenciation de fibrocytes
KR100368563B1 (ko) 안티-d면역글로불린g농축액및이를함유하는약제학적제제의제조방법
KR20230130681A (ko) Il-4r 길항제 투여에 의한 땅콩 알레르기를 치료하는방법 및 땅콩 알레르기원 특이적 면역치료를 강화하는 방법
KR20200110302A (ko) IgE-매개 알레르기성 질환들의 치료
Maggi et al. T cell clones providing helper function for IgE synthesis release soluble factor (s) that induce IgE production in human B cells: possible role for interleukin 4 (IL-4).
CA2320104A1 (fr) Procede de prevention et de traitement d'un trouble d'hypersensibilite de type i
D’Amato Therapy of allergic bronchial asthma with omalizumab–an anti-IgE monoclonal antibody
Berger Immunoglobulin products
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
Zuercher et al. Plasma-derived immunoglobulins
EP0648499B1 (fr) Composition pour l'inhibition de la production d'IgE
EP0973549A2 (fr) Composition intraveineuse d'immunoglobuline contenant un tensioactif non ionique aux proprietes pharmacocinetiques ameliorees
Rolinck-Werninghaus et al. Anti-IgE therapy in allergic asthma
Babu et al. The role of anti-IgE therapies in the treatment of asthma
Ramesh et al. Therapeutic uses of intravenous immunoglobulin (IVIG) in children
US20030103966A1 (en) Method to induce the Th1 immune response
Imbach Idiopathic thrombocytopenic púrpura
Rewald et al. IVIG-pools: regulatory gifts: Transiting from harmony toward harmonious immunoglobulins: why? and why not?
JPS62502119A (ja) 抗アレルゲン性阻止抗体の力価が高い免疫グロブリン製剤、その製法及びアレルギ−治療への使用
CN116887858A (zh) 通过施用il-4r拮抗剂治疗花生过敏并增强花生过敏原特异性免疫疗法的方法
US4721616A (en) Treatment of vernal conjunctivitis
US20050019321A1 (en) Method of obtaining protection against bystander allergen

Legal Events

Date Code Title Description
FZDE Dead